Carrers-Hope Pharmaceutical_Focused on drug research and development

Contact Us

——

Carrers

Recruitment

Carrers

[Exciting News] Haibu Pharmaceutical's Ibrutinib Capsules have received the second domestic drug registration approval.

Recently, the ibrutinib capsules (140mg) independently developed by Haibu Pharmaceutical have obtained the production approval, making it the second company in China to receive approval for this product after Xiansheng Pharmaceutical.

[Haibu Pharmaceutical] Pregabalin oral solution has successfully been selected in the tenth batch of national centralized procurement!

The oral solution of Ruianxi® Pregabalin has successfully been selected in the tenth batch of national procurement! This is not only a high recognition of Haibu Pharmaceutical's compliance qualifications and product quality, but also a great blessing for many patients.

Invitation | Haibu Pharmaceutical invites you to the 15th Taizhou International Medical Expo, visit booth E26/27

Haibu Pharmaceutical (Booth No: E26/27) is participating in the 15th China (Taizhou) International Pharmaceutical Expo. We welcome you to visit our booth for discussions.

Invitation | Haibu Pharmaceutical invites you to gather at the 【89th National Pharmaceutical Trade Fair】 booth A4L08

The National Pharmaceutical Trade Fair (PHARMCHINA) is a highly influential professional event in the field of pharmaceutical formulations and health in China, held twice a year in spring and autumn.

Glorious Moment丨Haibu Pharmaceutical has received multiple honors!

Beijing Haibu Pharmaceutical Technology Co., Ltd. has been honored as one of the "Top 50 R&D Companies in the Pharmaceutical Industry for 2023-2024", marking another consecutive year for Haibu Pharmaceutical to receive this accolade.

【Announcement】Beijing Haibu Pharmaceutical Technology Co., Ltd. Hazardous Waste Pollution Prevention and Control Information Announcement

According to the requirements of the "Law of the People's Republic of China on the Prevention and Control of Environmental Pollution by Solid Waste", units that generate solid waste shall timely disclose information on solid waste pollution to the environment in accordance with the law and actively accept social supervision.

【Good News】Haibu Pharmaceutical's Riluzole raw material has obtained the FDA registration number in the United States.

Our company has a wide variety of raw materials with stable supply. Welcome to inquire. Mr. Wei: 18515385101; Mr. Wu: 15600038801

【Good News】Haibu Pharmaceutical's Riluzole Tablets (40mg) have obtained clinical trial approval.

Introduction: The indications are to improve the following symptoms of uterine fibroids (excessive menstruation, lower abdominal pain, back pain, anemia); to alleviate the pain of endometriosis.

【Good News】Haibu Pharmaceutical's Isavuconazole Sulfate API has obtained the CDE registration number.

Haibu Pharmaceutical has a wide variety of raw materials, welcome to inquire.

【Good News】Haibu Pharmaceutical's pregabalin oral solution has obtained a production license.

Pregabalin oral solution has obtained production approval [National Drug Standard H20244981], used for the treatment of postherpetic neuralgia; fibromyalgia; and as an adjunctive treatment for partial seizures in adults.

Beijing Hope Pharmaceutical Co., Ltd.

SEO

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.